G-CSF for recurrent pregnancy loss

G-CSF trial for patients with unexplained recurrent pregnancy loss - G-CSF trial for patients with unexplained recurrent pregnancy loss

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041180087

Enrollment

Registered

2019-03-12

Start date

2010-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent pregnancy loss Recurrent pregnancy loss

Interventions

G-CSF group: Subcutaneous injection 20 g/body/day of Lenograstim (Neutrogin) 3 times every week from 4 gestational week to 7 gestational week and 6 day. Placebo group: 1 ml normal saline subcutaneous

D018873

Live-Birth rate

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.primary recurrent pregnancy loss 2.diagnosed unexplained pregnancy loss after several tests 3.recurrent early pregnancy loss over 3 times including normal fetal karyotype miscarriage

Exclusion criteria

Exclusion criteria: 1.Allergy for G-CSF 2.Participated in this clinical trial

Design outcomes

Primary

Measure	Time frame
Live-Birth rate	—

Secondary

Measure	Time frame
1.Growth and development of child(until 6 years old) 2.Side effect for patient	—

Contacts

Public ContactTamao Kitaori

Nagoya City University Hospital

tama-og@med.nagoya-cu.ac.jp+81-52-853-8241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026